Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High

Thursday, November 26, 2009 General News
Email Print This Page Comment
Font : A-A+



EXTON, Pa., Nov. 25 BioTrends Research Group, Inc. released Wave 1 of its LaunchTrends(TM): Stelara report, the first in a multi-phase syndicated market research project tracking the launch of Centocor Ortho-Biotech's Stelara, from product launch through the first six months of availability. Each wave of the report provides quantitative information from 75 unique Dermatologists and qualitative information from a subset of 20. The reports assess trial and use of Stelara, obstacles to use, typical patient types, product perceptions, promotional efforts/messages, and satisfaction with the product relative to other approved psoriasis agents.

Virtually all Dermatologists are aware of Stelara and interest in the product is high. Dermatologists view the required health care professional administration and the quarterly maintenance doing option as an advantage compared to other available biologic agents. On the downside, Dermatologists express concerns regarding the difficulty in obtaining managed care approval which has caused delays in the fulfillment of prescriptions for Stelara to date. Stelara uptake may also be somewhat blunted by the shadow of this year's withdrawal of Genentech's Raptiva related to serious adverse events. According to one respondent, "It kind of shell shocked us a little bit and we're always a bit leery about new agents."

Despite these concerns, there is strong interest in Stelara among Dermatologists. Nearly one-third of those surveyed have already prescribed the drug during the first month following launch. Among those who have yet to prescribe, 32% anticipate a product trial in the next three months. Considering the dominant market share position of Enbrel, it is not surprising that Stelara uptake is projected to have the greatest impact on Enbrel use.

The next wave of research will be conducted in January 2010 at three months post launch.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

Media Contact:Jennifer Robinson610-363-3872

SOURCE BioTrends Research Group, Inc.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook